Research into more clinical indications is ongoing, including IL-6 driven diseases: large-vessel vasculitis, type I IFN-related diseases: monogenic interferonopathies, scleroderma, myositis, and primary Sjogren’s syndrome. This evidence concerns the gene IL6 and scleroderma.